# Enhanced prognostic and immunomodulatory effects of novel cuproptosis-related long noncoding RNAs in wilms tumor

## TL;DR

This study creates a model using specific long non-coding RNAs to predict outcomes and treatment responses in children with Wilms tumor.

## Contribution

A novel cuproptosis-related lncRNA signature is introduced for prognosis and immunotherapy prediction in Wilms tumor.

## Key findings

- An eight lncRNA signature was developed, with high-risk patients showing worse outcomes.
- The low-risk group showed higher tumor immune dysfunction and better drug sensitivity.
- The model demonstrated good diagnostic performance for predicting prognosis and treatment response.

## Abstract

This study aims to develop a model for long non-coding RNA (lncRNA) associated with cuproptosis and assess the efficacy of immunotherapy and chemotherapy in children with Wilms tumor (WT) based on individualized risk scores.

Data was obtained from the online database. Cox proportional hazards analysis and LASSO Cox regression were employed to generate cuproptosis-related lncRNA signatures. Patients were classified into high- and low-risk groups and clinical outcomes were further analysed. Tumor mutation burden and immunoinfiltration were calculated and potential immunotherapy response was evaluated. The sensitivity of immunotherapy and chemotherapy was ultimately analyzed based on individual risk scores associated with cuproptosis.

A eight cuproptosis-related lncRNAs signature was established and high-risk group showed a worse prognosis than the low-risk group. This model showed a good diagnostic performance. Low-risk group displayed an elevated tumor immune dysfunction and was more sensitive to 13 drugs.

The current study introduces a novel approach for predicting clinical prognosis and determining the appropriate therapy for patients with WT.